TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8858463

Group type: EXPERIMENTAL
Intervention: 1 mg/kg ILd‐AmB (group A)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg ILd‐AmB (group B)
Number of subjects: 15
Study: 1639582

Group type: EXPERIMENTAL
Intervention: Heterologous lyophilized collagen sponge
Number of subjects: 72

Group type: COMPARATOR
Intervention: Dextranomer
Number of subjects: 72
Study: 6733006

Group type: EXPERIMENTAL
Intervention: Penbutolol (40 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Propranolol L.A. (160 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30965312

Group type: EXPERIMENTAL
Intervention: Narrow cuff (39.3 discomfort rating)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Wide cuff inflated to narrow cuff pressure (44 discomfort rating)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Wide cuff
Number of subjects: 233
Study: 30051623

Group type: EXPERIMENTAL
Intervention: CBT‐AN with LEAP
Number of subjects: 78

Group type: COMPARATOR
Intervention: CBT‐AN alone
Number of subjects: 78
Study: 27357182

Group type: EXPERIMENTAL
Intervention: Anagliptin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 50
Study: 24594972

Group type: EXPERIMENTAL
Intervention: Website only
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Website plus HCP support
Number of subjects: 143

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 143
Study: 22628490

Group type: EXPERIMENTAL
Intervention: Oral treprostinil
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Oral treprostinil (1.25 to 3.25 mg)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Oral treprostinil (3.5 to 16 mg)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study: 19028384

Group type: EXPERIMENTAL
Intervention: Letrozole (LE)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Clomiphene (CC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Natural cycles
Number of subjects: 30
Study: 17336501

Group type: EXPERIMENTAL
Intervention: Didactic training via CD‐ROM and two remote training sessions
Number of subjects: 12
Study: 15653083

Group type: COMPARATOR
Intervention: 1-year exercise program (n=34)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Posterolateral fusion without pedicle screw instrumentation (n=37)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Posterolateral fusion with pedicle screw instrumentation (n=40)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Surgical patients (combined instrumented and non-instrumented)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Conservative treatment (1-year exercise program)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Quality of life (SF-36)
Number of subjects: 111
Study: 12165396

Group type: EXPERIMENTAL
Intervention: D-penicillamine treatment for 24 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (22 controls)
Number of subjects: 32
Study: 10036338

Group type: EXPERIMENTAL
Intervention: 75 g liquid carbohydrate with 14.5 g encapsulated guar gum (FIB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 75 g liquid carbohydrate (GLU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (CON)
Number of subjects: 0
Study: 7671361

Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 2046

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2046
Study: 2085083

Group type: EXPERIMENTAL
Intervention: Atracurium administered by a priming technique (0.1 mg/kg i.v. followed by 0.5 mg/kg after 6 min)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Atracurium bolus injection (0.6 mg/kg)
Number of subjects: 44
Study: 464573

Group type: EXPERIMENTAL
Intervention: Gentamicin, vancomycin, and nystatin (GVN)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Gentamicin and nystatin (GN)
Number of subjects: 38
Study: 31961447

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New treatment
Number of subjects: 0
Study: 30375032

Group type: EXPERIMENTAL
Intervention: mobile health based Preterm Home Care Program (mHealthPHCP) known as 'NeoRaksha' mobile health application
Number of subjects: 300

Group type: COMPARATOR
Intervention: standard preterm care
Number of subjects: 300
Study: 28476271

Group type: EXPERIMENTAL
Intervention: Physician brief intervention for unhealthy alcohol use
Number of subjects: 3811

Group type: COMPARATOR
Intervention: Non-physician providers and medical assistants intervention
Number of subjects: 3811
Study: 26166595

Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Exercise therapy
Number of subjects: 24
Study: 22302619

Group type: EXPERIMENTAL
Intervention: Pseudo-IOCv2 scores obtained from linear regression models
Number of subjects: 1828

Group type: EXPERIMENTAL
Intervention: Linear regression models for predicting IOCv2 items
Number of subjects: 1828
Study: 21402241

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 19735164

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17721249

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine (10-ml bolus followed by an infusion of 10 ml/h during 48 h)
Number of subjects: 42

Group type: COMPARATOR
Intervention: 0.9% NaCl (placebo control)
Number of subjects: 42
Study: 15090815

Group type: EXPERIMENTAL
Intervention: Nevirapine 200 mg twice a day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 0
Study: 11419728

Group type: EXPERIMENTAL
Intervention: Optimized hazelnut extract
Number of subjects: 53

Group type: COMPARATOR
Intervention: Commercially available hazelnut extract (Soluprick)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Skin prick test (SPT) for milk
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Skin prick test (SPT) for egg
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Skin prick test (SPT) for wheat
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Skin prick test (SPT) for hazelnut
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Skin prick test (SPT) for cod
Number of subjects: 53
Study: 9778665

Group type: EXPERIMENTAL
Intervention: Ketamine (target plasma concentrations of 50, 100, 150, and 200 ng/ml)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7820215

Group type: EXPERIMENTAL
Intervention: Thyroid hormone replacement therapy
Number of subjects: 100
Study: 2201729

Group type: EXPERIMENTAL
Intervention: Zopiclone (5 or 7.5 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Triazolam (0.125 or 0.25 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 414196

Group type: COMPARATOR
Intervention: Inhaled cromolyn sodium (Intal)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral theophylline (Slo-Phyllin tablets, 7.5 mg/kg)
Number of subjects: 12
Study: 30715250

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)-informed strategy (CRP ≥80 mg/L plus age/temperature-corrected tachypnea and/or chest indrawing)
Number of subjects: 1726

Group type: COMPARATOR
Intervention: Current World Health Organization standard (respiratory rate ≥50 breaths/minute)
Number of subjects: 1726
Study: 28715532

Group type: EXPERIMENTAL
Intervention: Carboplatin
Number of subjects: 291

Group type: COMPARATOR
Intervention: Non-carboplatin
Number of subjects: 291

Group type: COMPARATOR
Intervention: Non-carboplatin (BRCA1/BRCA2 mutations)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Non-carboplatin (no BRCA1/BRCA2 mutations)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Carboplatin (no BRCA1/BRCA2 mutations)
Number of subjects: 291
Study: 24874549

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention to reduce at-risk drinking
Number of subjects: 631

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 631
Study: 23557073

Group type: EXPERIMENTAL
Intervention: Gout
Number of subjects: 1689

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1689
Study: 22036191

Group type: EXPERIMENTAL
Intervention: Hot biopsy forceps
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cold biopsy forceps
Number of subjects: 40
Study: 20109998

Group type: EXPERIMENTAL
Intervention: 0.05% CPC mouth rinse
Number of subjects: 117

Group type: COMPARATOR
Intervention: Fluoride mouth rinse
Number of subjects: 117
Study: 22542612

Group type: EXPERIMENTAL
Intervention: GA combined with pre‐emptive nerve stimulator‐guided pudendal nerve block (PNB) with 10 mL of 0.25% bupivacaine on each side
Number of subjects: 130

Group type: COMPARATOR
Intervention: GA alone
Number of subjects: 130
Study: 16078390

Group type: EXPERIMENTAL
Intervention: Subgroup analyses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Common regulatory claims based on subgroup analyses
Number of subjects: 0
Study: 12956499

Group type: EXPERIMENTAL
Intervention: EMG-based bruxism recording system
Number of subjects: 56
Study: 10435232

Group type: EXPERIMENTAL
Intervention: SCT-based intervention
Number of subjects: 260

Group type: COMPARATOR
Intervention: Knowledge-based intervention
Number of subjects: 260
Study: 8001387

Group type: EXPERIMENTAL
Intervention: Ultrasonic technique
Number of subjects: 76

Group type: COMPARATOR
Intervention: Traditional 'blind' technique (control)
Number of subjects: 76
Study: 1691287

Group type: EXPERIMENTAL
Intervention: Isoprinosine 4 g/day (1 g q.i.d.) + Ribavirin 800 mg/day
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Isoprinosine 4 g/day (1 g q.i.d.) + Ribavirin 1200 mg/day
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Treatment (Ribavirin and Isoprinosine)
Number of subjects: 15
Study: 6779148

Group type: EXPERIMENTAL
Intervention: Persantine plus Aspirin (PR/A)
Number of subjects: 2026

Group type: EXPERIMENTAL
Intervention: Aspirin alone (ASA)
Number of subjects: 2026

Group type: COMPARATOR
Intervention: Placebo (PLBO)
Number of subjects: 2026
Study: 12190281

Group type: EXPERIMENTAL
Intervention: Video instruction
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Verbal instruction
Number of subjects: 30

Group type: COMPARATOR
Intervention: Self-guided instruction
Number of subjects: 30
Study: 31116964

Group type: EXPERIMENTAL
Intervention: Adrenaline
Number of subjects: 7848

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7848
Study: 29938584

Group type: EXPERIMENTAL
Intervention: Poor recovery group (ARAT ≤9 points)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Good recovery group (ARAT ≥10 points)
Number of subjects: 36
Study: 26716589

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft (CABG) surgery
Number of subjects: 1315

Group type: COMPARATOR
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1315
Study: 24813558

Group type: EXPERIMENTAL
Intervention: Acupuncture plus diet (n=32)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Diet only (n=32)
Number of subjects: 64
Study: 22652276

Group type: EXPERIMENTAL
Intervention: Adherence to SEMT guidelines for medical history
Number of subjects: 1790

Group type: EXPERIMENTAL
Intervention: Adherence to SEMT guidelines for physical examination
Number of subjects: 1790

Group type: EXPERIMENTAL
Intervention: Adherence to SEMT guidelines for laboratory evaluations
Number of subjects: 1790

Group type: EXPERIMENTAL
Intervention: Overall guideline adherence
Number of subjects: 1790

Group type: EXPERIMENTAL
Intervention: Adherence based on age and gender
Number of subjects: 1790

Group type: EXPERIMENTAL
Intervention: Adherence by institution type
Number of subjects: 1790
Study: 20739720

Group type: EXPERIMENTAL
Intervention: Taurine (1.66 g)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (nothing added)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (nothing added, participants told they received taurine)
Number of subjects: 11
Study: 17654298

Group type: EXPERIMENTAL
Intervention: Telephone booster sessions after intensive inpatient treatment
Number of subjects: 290

Group type: COMPARATOR
Intervention: Standard group smoking cessation program without telephone booster sessions
Number of subjects: 290
Study: 15941534

Group type: EXPERIMENTAL
Intervention: Multiple micronutrients supplementation (vitamin A 600 microg, beta-carotene 1.0 mg, vitamin E 100 mg, vitamin C 300 mg, Na2SeO3 200 microg daily for 8 weeks)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (placebo tablet)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Multiple micronutrients supplementation
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 82
Study: 12044624

Group type: EXPERIMENTAL
Intervention: Regular opioids plus low dose intravenous ketamine (0.6 mg/kg)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Regular opioids plus placebo
Number of subjects: 35
Study: 10442368

Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel by 1-hour infusion plus UFT/oral calcium folinate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 0
Study: 8848885

Group type: EXPERIMENTAL
Intervention: Lidocaine 2% with glucose 8% (H group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lidocaine 2% plain (P group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (P and H)
Number of subjects: 40
Study: 2349134

Group type: EXPERIMENTAL
Intervention: Diltiazem 60 mg orally four times a day for 1 week
Number of subjects: 6

Group type: COMPARATOR
Intervention: Propranolol 40 mg orally four times a day for 1 week
Number of subjects: 6
Study: 367411

Group type: EXPERIMENTAL
Intervention: Caffeine 75 to 300 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cyclizine 25 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cyclizine 100 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Caffeine 100 mg + Cyclizine 50 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Caffeine 100 mg + Cyclizine 100 mg
Number of subjects: 12
Study: 30507733

Group type: EXPERIMENTAL
Intervention: Back squats with PAP
Number of subjects: 10
Study: 30690866

Group type: EXPERIMENTAL
Intervention: DASH diet with high sodium (150 meq/d)
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: DASH diet with low sodium (50 meq/d)
Number of subjects: 412

Group type: COMPARATOR
Intervention: Typical Western diet (control)
Number of subjects: 412
Study: 28072706

Group type: EXPERIMENTAL
Intervention: GemCap (oral capecitabine 1660 mg/m plus Gem 1000 mg/m by 30‐minute intravenous infusion weekly for 3 weeks followed by a 1‐week break every 4 weeks)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Gem (by 30‐minute intravenous infusion weekly for 3 weeks every 4 weeks)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: GemCap
Number of subjects: 214

Group type: COMPARATOR
Intervention: Gem
Number of subjects: 214
Study: 26468172

Group type: EXPERIMENTAL
Intervention: Ultrasound and exercise
Number of subjects: 49

Group type: COMPARATOR
Intervention: Corticosteroid injection (1mL triamcinolone acetonide 10mg/mL and 1mL lidocaine 2%)
Number of subjects: 49
Study: 23104564

Group type: EXPERIMENTAL
Intervention: Combination therapy (vitamin D 600,000 IU single intramuscular dose + calcium 75 mg/kg/day elemental calcium orally)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Vitamin D alone (600,000 IU single intramuscular dose)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Calcium alone (75 mg/kg/day elemental calcium orally)
Number of subjects: 67
Study: 21503388

Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 372

Group type: COMPARATOR
Intervention: Clinical treatment
Number of subjects: 372
Study: 19839894

Group type: EXPERIMENTAL
Intervention: Monocanalicular intubation
Number of subjects: 54

Group type: COMPARATOR
Intervention: Bicanalicular intubation
Number of subjects: 54
Study: 16988850

Group type: EXPERIMENTAL
Intervention: Botulinum toxin plus glyceryl trinitrate (Group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Botulinum toxin plus placebo paste (Group B)
Number of subjects: 30
Study: 12505939

Group type: EXPERIMENTAL
Intervention: Clonidine (EC group)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Midazolam (EM group)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Clonidine (YC group)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Clonidine (YC‐HP group)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Clonidine (EC‐LP group)
Number of subjects: 64
Study: 11272970

Group type: EXPERIMENTAL
Intervention: Continuous infusion (CI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intermittent flushing (IF)
Number of subjects: 0
Study: 8894432

Group type: EXPERIMENTAL
Intervention: Oxiconazole nitrate cream, 1 percent (monotherapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy with oxiconazole nitrate cream, 1 percent and fluticasone propionate cream, 0.05 percent
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study: 1899409

Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study: 6349785

Group type: EXPERIMENTAL
Intervention: BCNU (80 mg/m2/day IV X 3 and repeat every 8 weeks)
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: methyl‐CCNU (125 mg/m2/day orally X 1 and repeat every 8 weeks) + DTIC (150 mg/m2/day IV X 5 and repeat every 4 weeks)
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Higher radiation dose (7000 rad/8-9 weeks)
Number of subjects: 626

Group type: COMPARATOR
Intervention: Control radiation (6000 rad/6-7 weeks to whole brain)
Number of subjects: 626
Study: 31931750

Group type: EXPERIMENTAL
Intervention: Ultrasonography (US) usage among GPs
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Ultrasonography (US) for fracture diagnosis
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Knowledge about ultrasonographic fracture diagnosis
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Comparison of US and conventional X-rays
Number of subjects: 286

Group type: COMPARATOR
Intervention: Knowledge and usage of US for fracture diagnosis
Number of subjects: 286
Study: 30781936

Group type: EXPERIMENTAL
Intervention: Kinect2Scratch game training
Number of subjects: 33

Group type: COMPARATOR
Intervention: Therapist-based training
Number of subjects: 33
Study: 28360825

Group type: EXPERIMENTAL
Intervention: Oxygen supplement (OS)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (taste matched)
Number of subjects: 25
Study: 25930208

Group type: EXPERIMENTAL
Intervention: Aliskiren
Number of subjects: 1615

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1615
Study: 23999845

Group type: EXPERIMENTAL
Intervention: Recovery-focused group intervention led by peer counselors and professional counselors
Number of subjects: 82
Study: 21807562

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Endoscopic injection
Number of subjects: 203

Group type: COMPARATOR
Intervention: Surveillance
Number of subjects: 203
Study: 19567163

Group type: EXPERIMENTAL
Intervention: Homoharringtonine (HHT) 1.5 mg/m² by continuous daily infusion for seven to nine days every four weeks
Number of subjects: 106

Group type: COMPARATOR
Intervention: Interferon alpha (IFN‐alpha)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Hydroxycarbamide
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: HHT as salvage treatment for patients who failed IFN‐alpha
Number of subjects: 106
Study: 17012656

Group type: EXPERIMENTAL
Intervention: Standardised outcome assessment (monthly postal questionnaires and 3-monthly feedback)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 160
Study: 15007003

Group type: EXPERIMENTAL
Intervention: Warfarin use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sinus rhythm (SR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drugs (AADs)
Number of subjects: 0
Study: 11054217

Group type: EXPERIMENTAL
Intervention: Inelastic compression bandages (Unna boots on the lower leg, adhesive bandages on the thigh)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Thigh‐length compression stockings, class II
Number of subjects: 45

Group type: COMPARATOR
Intervention: Bed rest with no compression
Number of subjects: 45
Study: 9507837

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 20 mg phentolamine
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 40 mg phentolamine
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 60 mg phentolamine
Number of subjects: 44
Study: 8042808

Group type: EXPERIMENTAL
Intervention: Mivacurium chloride (0.15 mg.kg‐1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Succinylcholine (1 mg.kg‐1)
Number of subjects: 30
Study: 3055819

Group type: EXPERIMENTAL
Intervention: Percutaneous estradiol gel
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 22
Study: 29543547

Group type: EXPERIMENTAL
Intervention: ROTAVAC® with citrate-bicarbonate buffer (Group I)
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: ROTAVAC® alone without buffer (Group II)
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: ROTAVAC® mixed with buffer (Group III)
Number of subjects: 900

Group type: COMPARATOR
Intervention: All groups (I, II, III)
Number of subjects: 900
Study: 28415065

Group type: EXPERIMENTAL
Intervention: Localized vibration (30 Hz) to 4 selected lower-body areas
Number of subjects: 21

Group type: COMPARATOR
Intervention: Moderately low-resistance stationary cycling (70 rpm)
Number of subjects: 21
Study: 26429297

Group type: EXPERIMENTAL
Intervention: Busulfan plus cyclophosphamide
Number of subjects: 252

Group type: COMPARATOR
Intervention: Busulfan plus fludarabine
Number of subjects: 252
Study: 23358639

Group type: EXPERIMENTAL
Intervention: Protease inhibitor (PI)-based antiretroviral therapy (ART)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-nucleoside reverse transcriptase inhibitor-based ART
Number of subjects: 0
Study: 21660428

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Social Recreational (SR)
Number of subjects: 70
Study: 18794000

Group type: EXPERIMENTAL
Intervention: Current techniques available in the management of hemorrhoids and anal fissures
Number of subjects: 0
Study: 16550052

Group type: EXPERIMENTAL
Intervention: Autologous platelet concentrate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (untreated side)
Number of subjects: 0